Nogapendekin alfa inbakicept: all 79 studies that test it

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruitingNCT07783789Phase 2
• Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNot yet recruitingNCT07756593Phase 1
• Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingNCT07628062Phase 2
• NAI for Sepsis With Persistent LymphopeniaNot yet recruitingNCT07578558Phase 2
• Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNot yet recruitingNCT07574541Phase 2
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2
• N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapyRecruitingNCT07261657Early Phase 1
• N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
• Interleukin-15 to Promote Post-ART Control of HIVEnrolling by invitationNCT07145164Phase 2
• A Study to Examine Anktiva for the Treatment of COVID-19.RecruitingNCT07123727Phase 2
• A Study to Assess Anktiva in Patients With Long Covid-19.RecruitingNCT07108036Phase 2
• A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaRecruitingNCT07085338Phase 2
• Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingNCT06829823Phase 2
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InRecruitingNCT06745908Phase 3
• A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingNCT06710288Phase 2
• Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/2
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingNCT06239220Phase 2
• Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecruitingNCT05618925Phase 1
• Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV DiseaseCompletedNCT04808908Phase 1Results posted
• Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19TerminatedNCT04385849Phase 1Results posted
• Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus InfectionCompletedNCT04247282Phase 1/2Results posted
• QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyTerminatedNCT03853317Phase 2Results posted
• QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedNCT03586869Phase 1/2Results posted
• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedNCT03493945Phase 1/2Results posted
• QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedNCT03387111Phase 1/2Results posted
• QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03387098Phase 1/2Results posted
• QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedNCT03387085Phase 1/2Results posted
• QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803CompletedNCT03381586Phase 1Results posted
• QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03329248Phase 1/2Results posted
• QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03136406Phase 1/2Results posted
• QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerTerminatedNCT03127098Phase 1/2Results posted
• IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
• QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AMLCompletedNCT03050216Phase 2Results posted
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
• Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell TransplantationActive, not recruitingNCT02782546Phase 2Results posted
• ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02523469Phase 1/2Results posted
• QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2Results posted
• QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02099539Phase 1Results posted
• A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid TumorsCompletedNCT01946789Phase 1Results posted
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT01898793Phase 1/2Results posted
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
• ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerWithdrawnNCT07551544Phase 3
• Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCWithdrawnNCT07524257Phase 3
• Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)WithdrawnNCT07492888Phase 2
• Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaWithdrawnNCT07492875Phase 3
• Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnNCT07488884Phase 1
• N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasWithdrawnNCT07049432Phase 1
• Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.WithdrawnNCT06765954Phase 2
• Immunotherapy Before and After SurgeryWithdrawnNCT06765902Phase 2
• Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By ApheresisCompletedNCT06040918Phase 1
• Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnNCT05769569Phase 1
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
• 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)CompletedNCT05245292Phase 1
• Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWithdrawnNCT05007769Phase 2
• Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2
• Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV InfectionActive, not recruitingNCT04505501Phase 2
• Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT04390399Phase 2
• QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
• QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnNCT03574649Phase 2
• QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
• QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
• QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnNCT03554109Phase 2
• Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
• QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
• QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
• QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
• QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
• QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
• QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
• QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
• QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
• QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingNCT03022825Phase 2/3
• Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
• QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-PaclitaxelCompletedNCT02559674Phase 1
• Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected PeopleCompletedNCT02191098Phase 1
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerActive, not recruitingNCT02138734Phase 1/2

← Nogapendekin alfa inbakicept overview